Switch theme
Sign up to access all valuation multiples
GlaxoSmithKline Pakistan Ltd is engaged in the research, development, and manufacturing of pharmaceutical medicines, vaccines, and consumer healthcare products. It is involved in Anti-infective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular, and Vitamins therapy areas. The operating business divisions are Pharmaceuticals and Consumer Healthcare. The pharmaceutical brands of the company include Augmentin, Seretide, Amoxicillin, Velosef, Zantac, and Calpol, and prominent vaccines include Synflorix, Infanrix Hexa, Rotarix, Engerix-B, Havrix, and Cervarix. The company derives maximum revenue from the Pharmaceuticals segment.
2001
1.7K+
LTM Revenue $226M
Last FY EBITDA $41.4M
$408M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
GlaxoSmithKline Pakistan has a last 12-month revenue (LTM) of $226M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, GlaxoSmithKline Pakistan achieved revenue of $217M and an EBITDA of $41.4M.
GlaxoSmithKline Pakistan expects next 12-month revenue of XXX and NTM EBITDA of XXX
See GlaxoSmithKline Pakistan valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $226M | XXX | $217M | XXX | XXX | XXX |
| Gross Profit | $63.1M | XXX | $54.7M | XXX | XXX | XXX |
| Gross Margin | 28% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $41.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 19% | XXX | XXX | XXX |
| EBIT | $39.4M | XXX | $36.0M | XXX | XXX | XXX |
| EBIT Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $28.4M | XXX | $23.2M | XXX | XXX | XXX |
| Net Margin | 13% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, GlaxoSmithKline Pakistan's stock price is PKR 379 (or $1).
GlaxoSmithKline Pakistan has current market cap of PKR 121B (or $428M), and EV of PKR 115B (or $408M).
See GlaxoSmithKline Pakistan trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $408M | $428M | XXX | XXX | XXX | XXX | $0.09 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, GlaxoSmithKline Pakistan has market cap of $428M and EV of $408M.
GlaxoSmithKline Pakistan's trades at 1.9x EV/Revenue multiple, and 9.9x EV/EBITDA.
Equity research analysts estimate GlaxoSmithKline Pakistan's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
GlaxoSmithKline Pakistan has a P/E ratio of 15.1x.
See valuation multiples for GlaxoSmithKline Pakistan and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $428M | XXX | $428M | XXX | XXX | XXX |
| EV (current) | $408M | XXX | $408M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBIT | 10.4x | XXX | 11.3x | XXX | XXX | XXX |
| EV/Gross Profit | 6.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 15.1x | XXX | 18.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 50.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGlaxoSmithKline Pakistan's last 12 month revenue growth is 8%
GlaxoSmithKline Pakistan's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $11K for the same period.
GlaxoSmithKline Pakistan's rule of 40 is 15% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
GlaxoSmithKline Pakistan's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for GlaxoSmithKline Pakistan and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | 8% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 19% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 15% | XXX | 28% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $11K | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
GlaxoSmithKline Pakistan acquired XXX companies to date.
Last acquisition by GlaxoSmithKline Pakistan was XXXXXXXX, XXXXX XXXXX XXXXXX . GlaxoSmithKline Pakistan acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was GlaxoSmithKline Pakistan founded? | GlaxoSmithKline Pakistan was founded in 2001. |
| Where is GlaxoSmithKline Pakistan headquartered? | GlaxoSmithKline Pakistan is headquartered in Pakistan. |
| How many employees does GlaxoSmithKline Pakistan have? | As of today, GlaxoSmithKline Pakistan has 1.7K+ employees. |
| Is GlaxoSmithKline Pakistan publicy listed? | Yes, GlaxoSmithKline Pakistan is a public company listed on KAR. |
| What is the stock symbol of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan trades under GLAXO ticker. |
| When did GlaxoSmithKline Pakistan go public? | GlaxoSmithKline Pakistan went public in 1953. |
| Who are competitors of GlaxoSmithKline Pakistan? | Similar companies to GlaxoSmithKline Pakistan include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan's current market cap is $428M |
| What is the current revenue of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan's last 12 months revenue is $226M. |
| What is the current revenue growth of GlaxoSmithKline Pakistan? | GlaxoSmithKline Pakistan revenue growth (NTM/LTM) is 8%. |
| What is the current EV/Revenue multiple of GlaxoSmithKline Pakistan? | Current revenue multiple of GlaxoSmithKline Pakistan is 1.8x. |
| Is GlaxoSmithKline Pakistan profitable? | Yes, GlaxoSmithKline Pakistan is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
